Depatuxizumab, a brain-penetrant, humanized anti-EGFR monoclonal antibody, selectively inhibits the growth of mutant EGFRvIII and wild-type EGFR xenograft models, and is utilized for research on cancer [1].

Depatuxizumab administered intraperitoneally (i.p.) at doses of 10 and 40 mg/kg three times per week for two weeks significantly inhibited tumor growth in the U87MG delta-2-7 glioblastoma (GBM) variant model and the A431 epidermoid carcinoma model in Nu/Nu mice [1]. The same treatment regimen with depatuxizumab suppressed tumor growth and levels of phosphorylated EGFR (pEGFR) in the EGFRvIII-positive GBM-SN0199-PDX model in NSG mice [1]. Moreover, depatuxizumab demonstrated dose-dependent inhibition of tumor growth in the SCC15 tumor-bearing SCID Beige mouse model when administered at concentrations ranging from 2 to 40 mg/kg [1].